Exxua Charts a New Path in Depression Treatment Following FDA Nod
XTalks
SEPTEMBER 28, 2023
The company initially submitted a New Drug Application (NDA) Amendment to the FDA on December 23, 2022. “Exxua represents an important milestone in the treatment of MDD, a serious and debilitating condition that affects millions of people worldwide,” said Stephen Kramer, MD, CEO of Fabre-Kramer, in the company’s news release.
105 
Let's personalize your content